bims-stacyt Biomed News
on Metabolism and the paracrine crosstalk between cancer and the organism
Issue of 2021–09–19
three papers selected by
Cristina Muñoz Pinedo, L’Institut d’Investigació Biomèdica de Bellvitge



  1. Oncoimmunology. 2021 ;10(1): 1968611
      We recently reported that inhibiting Hypoxia-inducible Factor-1α (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author's View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.
    Keywords:  CCL5/Rantes; CD8 T-lymphocytes; Hypoxia; NK cells; anti-PD-1/PD-L1; cancer immunotherapy; chemokines; cold/hot tumors; hypoxia-inducible factor; immune landscape; melanoma
    DOI:  https://doi.org/10.1080/2162402X.2021.1968611
  2. Trends Endocrinol Metab. 2021 Sep 13. pii: S1043-2760(21)00201-0. [Epub ahead of print]
      Fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) are established as stress-responsive cytokines that can modulate energy balance by increasing energy expenditure or suppressing food intake, respectively. Despite their pharmacologically induced beneficial effects on obesity and comorbidities, circulating levels of both cytokines are elevated during obesity and related metabolic complications. On the other hand, endocrine crosstalk via FGF21 and GDF15 was also reported to play a crucial role in genetically modified mouse models of mitochondrial perturbations leading to diet-induced obesity (DIO) resistance. This review aims to dissect the complexities of endogenous FGF21 and GDF15 action in obesity versus DIO resistance for the regulation of energy balance in metabolic health and disease.
    Keywords:  FGF21; GDF15; adipose tissue; energy balance; mitochondrial integrated stress response; muscle; obesity resistance
    DOI:  https://doi.org/10.1016/j.tem.2021.08.008
  3. J Cell Physiol. 2021 Sep 12.
      Under nonpathological conditions, the extracellular nucleotide concentration remains constant and low (nM range) because of a close balance between ATP release and ATP consumption. This balance is completely altered in cancer disease. Adenine and uridine nucleotides are found in the extracellular space of tumors in high millimolar (mM) concentrations acting as extracellular signaling molecules. In general, although uridine nucleotides may be involved in different tumor cell responses, purinergic signaling in cancer is preferentially focused on adenine nucleotides and nucleosides. Extracellular ATP can bind to specific receptors (P receptors) triggering different responses, or it can be hydrolyzed by ectoenzymes bound to cell membranes to render the final product adenosine. The latter pathway plays an important role in the increase of adenosine in tumor microenvironment. In this study, we will focus on extracellular ATP and adenosine, their effects acting as ligands of specific receptors, activating ectoenzymes, and promoting epithelial-mesenchymal transition, migration, and invasion in cancer cells. Finding the roles that these nucleotides play in tumor microenvironment may be important to design new intervention strategies in cancer therapies.
    Keywords:  cancer; cell migration and invasion; epithelial-mesenchymal transition; extracellular ATP; extracellular adenosine; purinergic receptors
    DOI:  https://doi.org/10.1002/jcp.30580